News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Lithera Announces Company Name Change To Neothetics, Inc.

8/12/2014 7:52:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc., announced today that it has changed its name to Neothetics, Inc. The new name strengthens the company's positioning as a clinical-stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market.

"Our new name better identifies us with our corporate mission to develop and commercialize innovative therapies for the rapidly growing aesthetics market," said George Mahaffey, President and CEO of Neothetics. "We have successfully completed Phase 2 clinical trials for our lead product candidate, LIPO-202, and are currently engaged in planning Phase 3 clinical trials in accordance with FDA guidance. If approved, LIPO-202 has the potential to be a best-in-class, highly differentiated, non-surgical, injectable formulation for localized subcutaneous fat reduction and body contouring for healthy, non-obese patients. As we move closer to commercialization, it's important that our corporate identity is clear and compelling to both physicians and patients, which is why we are pleased to enter this transformational phase as Neothetics."

The name change to Neothetics, Inc. is effective immediately; the company's website is now available at

About Neothetics

Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. Our initial focus is on localized fat reduction and body contouring. We are currently developing and seeking approval for our lead product candidate, LIPO-202, for the reduction of subcutaneous fat in the central abdomenin non-obese patients, an indication for which there is no FDA-approved drug. If approved by the FDA, we believe LIPO-202 will be a best-in-class non-surgical procedure and first-in-class injectable formulation for localized fat reduction and body contouring. Founded in 2007, the Company has assembled an exceptional team of senior executives, employees and advisors and has been financed by top-tier venture capital firms. For more information on Neothetics, Inc., please visit

Neothetics, LIPO-202, LIPO-102, Lithera and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.

CONTACT: Neothetics, Inc. Contact: Susan A. Knudson Chief Financial Officer 858-750-1008 Investor Relations: Fara Berkowitz Argot Partners 212-600-1902

Neothetics Logo

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus